Last year saw an end-to-end meeting, bringing together an exclusive forum of leaders within R&D, CMC, manufacturing, supply chain, process development and analytics that are working to define gold standard approaches for donor characterization, testing and cell source procurement for safe and globally accessible off-the-shelf cell therapies.
What Can You Expect?
3
days of unmissable content covering key challenges from R&D, CMC, manufacturing, supply chain, process development and analytics
2
revitalized workshop sessions to take part in intimate discussions with KOLs from Poseida Therapeutics and CytoImmune Therapeutics
20+
hours of dedicated sessions covering the end-to-end scope of donor selection, screening, characterizing and making critical decisions to guarantee commercialization and marketing access
Must-Attend Sessions
Master regulatory challenges and best practices in donor selection for allogeneic therapies, ensuring compliance, quality assurance, effective documentation, and ethical standards across the US, Europe, and Asia with CytoImmune Therapeutics
Identify and validate phenotypic and functional signatures of healthy donor T-cells to predict and enhance the potency of hypoimmune CAR-T cells for superior therapeutic outcomes with Sana Biotechnology
Uncover the benchmark criteria for donor characterization to guarantee high-quality, safe, and effective donor materials, aiding in regulatory approval and enhancing therapeutic results with MiNK Therapeutics
Characterize HSC-derived NK cells to identify optimal donors using a cost-effective, high-throughput screening platform for large-scale expansion, revealing significant donor differences in proliferation, cytotoxicity, and in vivo function with ImmuneBridge
Examine strategies for ensuring donor product consistency throughout downstream drug development, enhancing product reliability, supporting regulatory compliance, and mitigating development risks with Bristol Myers Squibb
Who's Attending?
I felt that this was a very unique meeting where suppliers and consumers of blood products finally got in the same room to talk about the challenges and potential solutions to creating stable sources of apheresis units for allogeneic products
Senior Director - Chemistry, Manufacturing & Controls, Regulatory Affairs, Imugene - 2023 Attendee